Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors
2022-500694-14-00Phase 2Completed
- Sponsor
- BeiGene
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 2, open-label trial of surzebiclimab, alcestobart and tislelizumab in head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC) and clear cell renal cell carcinoma (ccRCC) (3 arms), sponsored by BeiGene. Primary endpoints: Adverse events and serious adverse events (Phase 1 dose escalation & Phase 2 safety lead-in), Maximum tolerated dose (MTD) or maximum administered dose (MAD) (Phase 1 dose escalation & Phase 2 safety lead-in) and 2 more. Started Oct 2022; status: completed.
02
Drugs
surzebiclimabalcestobarttislelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2022-500694-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500694-14-00.